Clinical Effects of Arotinolol in Essential Hypertension.
10.4070/kcj.1990.20.3.474
- Author:
Yang Kyu PARK
;
An Myung KIM
;
Jin Won JEONG
;
Ock Kyu PARK
- Publication Type:Original Article
- Keywords:
Hypertension;
Arotinolol
- MeSH:
Blood Pressure;
Bradycardia;
Cholesterol;
Cholesterol, HDL;
Coronary Disease;
Creatinine;
Extremities;
Heart Failure;
Heart Rate;
Hypertension*;
Hypesthesia;
Peripheral Vascular Diseases;
Triglycerides
- From:Korean Circulation Journal
1990;20(3):474-478
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
To evaluate the antihypertensive effect, side effects and metabolic changes of arotinolol, a combined alpha and beta blocker, 10-15mg of arotinolol twice a day was administered for 8 weeks in 27 hypertensives (168+/-16/106+/-10mmHg) without heart failure, bradycardia, conduction disturbance, coronary heart disease or renal impairment. Blood pressure decreased to 137+/-10/90+/-6mmHg and average reduction of systolic BP and diastolic BP were 31 mmHg(18%) and 16mmHg(15%) respectively. Pulse rate reduced significantly(p<0.01) after 2weeks' treatment of arotinolol and average reduction of pulse rate was 10 beats/min after 8weeks treatment. There were no significant changes of serum ALP, AST and ALT, BUN, and serum creatinine, Na+, K+, total cholesterol, HDL cholesterol and triglyceride. But in 8 patients(30%), insomina, sleepness, cold extrimities or numbness on extremities developed or aggravated. These results suggest that arotinolol be an useful antihypertensive agent in hypertensives without heart failure, bradyarrhythmais or peripheral vascular disease.
